٤.	5	

ų,

000023000780

Clerk of the House of Representatives	Secretary of the Senate
Legislative Resource Center	Office of Public Records
B-106 Canton Building	232 Hart Building
Muchington DC 20615	Workington, DC 20510
Washington, DC 20515	Washington, DC 20510

SECRETARY OF THE SENATE

OD AUG 10 ANTI: 17

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrated Name Bristol-Myers Squibb Cor	праку		
2. Address D Clock if differe 655 15th St., NW	int than previously reported Washington, DC 20005	USA	
 Principal Place of Business (if diff City 	erent from line 2) State/Zip (or Country)		
4. Contact Name Richard Thompson	Telephone E-mail (optional) (202) 783-0900		5. Senate ID# 7053-12
7. Client Name 🔀 Self			6. House ID # 7053

TYPE OF REPORT 8. Year 2000 Midyear (January J-June 30) 🕱 OR Year End (July 1-December 31) 🖺

9. Check if this filing amends a previously filed version of this report 🗍

10. Check if this is a Termination Report [] >> Termination Date

11. No Lobbying Activity 🗍

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
\$10,000 or more >> \$ Income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	 S10,000 or more ≤ >>\$ S2,440,000.00 Expenses (nearest \$20,000) 14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. ≤ Method A. Reporting amounts using LDA definitions only □ Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code □ Method C. Reporting amounts under section 162(e) of the Internal Revenue Code
Signature	Date <u>8/11/2000</u>

20 L L

· · · · • • •		000(23000780	
egistrant Name:	······································		
lient Name:	Self	•	
igaged in lobbyir		r to reflect the general issue areas in which the registrant ag period. Using a separate page for each code, provide	
. General issue	area code BUD (one per page)		
Lobbied to a H.R.4461, A 2001, Lobbid S.CON.RES 2005 and rev H.CON.RES and Medicai S.2553, Deps	culture, Rural Development, Food and D dd safety features to prescription drug is griculture, Rural Development, Food and d to add safety features to prescription d 101, Setting forth the congressional budg ising the budgetary levels for fiscal year .290, Resolved by the House of Represen d programs.	d Drug Administration, and Related Agencies Appropris lrug import provisions. get for the United States Government for fiscal years 20(2009, Lobbied for funding for Medkare and Medicaid p tatlves (the Senate concurring), Lobbied for funding for ervices, and Education, and Related Agencies Appropria	ations Act, 11 through programs. Medicare
Department	Congress and Federal agencies contacted of Agriculture presentatives	Check if None	
Name of each	individual who acted as a lobbyist in this i Name	Covered Official Position (if applicable)	New
	Name	Covered Official Position (1 applicable)	
Kcaney, Day	Narie id	Covered Official Position (if applicable)	No
Keaney, Day Carozza, Mi	Name id chael	Covered Official Position (if applicable)	No
Kcaney, Day Carozza, Mi	Narie id	Covered Official Position (if applicable)	No
Kcaney, Day Carozza, Mi	Name id chael	Covered Official Position (if applicable)	No
Kcaney, Day Carozza, Mi	Name id chael	Covered Official Position (if applicable)	No
Keansy, Day Carozza, Mi	Name id chael	Covered Official Position (if applicable)	No
Keansy, Day Carozza, Mi	Name id chael	Covered Official Position (if applicable)	No
Keaney, Day Carozza, Mi Thompson, f	Name id chael	Covered Official Position (if applicable)	No
Kcaney, Day Carozza, Mi Thompson, f	Name id chael tichard th foreign entity in the specific issues listed	Covered Official Position (if applicable)	No

		Squibb Company
Client i		
ltem 16	Description Lobbying issues	Data H.R.4577, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2001, Lobbled to increase funding for Ryan White program.
		· · ·
		· · ·
	l . l	
	·	

egistrant Name:	Bristol-Myers Squibb Comp	000(23.000780	
Dient Name:	Self		
ngaged in lobbyi		is necessary to reflect the general issue areas in which the registrant the reporting period. Using a separate page for each code, provide) as needed.	
5. General issu	e area code <u>CAW</u> (one	: per page)	
MACT. EPA:Pharm	Maximum Achievement Contra ascentical MACT, Jobbied to en	of Technology (MACT), lubbied to discourage EPA from issuing a sure technical changes to EPA's proposed pharmaceutical MACT ensure data quality and accessibility.	
Environme	Congress and Pederal agencies co atal Protection Agency presentatives	ontacted	
8. Name of cac	h individual who acted as a lobby Name	Covered Official Position (if applicable)	Ne
	Кале		
 Name of car Skrabut, La 	Кале	Covered Official Position (if applicable)	Ner Nu
	Кале	Covered Official Position (if applicable)	Ner Ng
	Кале	Covered Official Position (if applicable)	
	Кале	Covered Official Position (if applicable)	
	Кале	Covered Official Position (if applicable)	
	Кале	Covered Official Position (if applicable)	
Skrabut, La	Кале	Covered Official Position (if applicable)	

Danicemen XI-	Balatal Manage Carella L. Comme	. 000(23 00078 0	
Registrant Name:	Bristol-Myers Squibb Company		
Client Name;		·	
engaged in lobbyir	,	ssary to reflect the general issue areas in which the registrant orting period. Using a separate page for each code, provide sted.	
 General issue 	area code <u>CPT</u> (one per pa	ge)	
S.1258, Pater industry. S.1172, Drug industry. S.999, Techn S.804, Techn S.671, Madri H.R.1907, At H.R.1598, Pa	emark Amendments Act of 1999, M nt Fee Integrity and Innovation Prote Patent Term Restoration Review Pr eology Transfer Act of 1999, Monitor eology Transfer Commercialization A id Protocol Implementation Act, Mor merican Inventors Protection Act of thent Fairness Act of 1999, Monitor t	onitor the effect of the bill on the pharmaceutical industry, ection Act of 1999, Monitor the effect of the bill on the pha- rocedure Act of 1999, Monitor the effect of the bill on the pha- the effect of the bill on the pharmaceutical industry, act of 1999, Monitor the effect of the bill on the pharmaceut altor the effect of the bill on the pharmaceutical industry. 1999, Monitor the effect of the bill on the pharmaceutical in- he effect of the bill on the pharmaceutical industry. 1999, Monitor the effect of the bill on the pharmaceutical in- he effect of the bill on the pharmaceutical industry. Aonitor the effect of the bill on the pharmaceutical industry.	armaccutic ical industr dustry.
	Congress and Federal agencies contacted	d 🗍 Check if None	
•	of Commerce presentatives		
House of Rey Senate USTR		this issue area	
House of Rey Senate USTR	presentatives		New
House of Rey Senate USTR	presentatives Findividual who acted as a lobbyist in (Name	this issue area	New New
House of Rey Senate USTR 18. Name of each	presentatives Findividual who acted as a lobbyist in (Name	this issue area	
House of Reg Senate USTR 18. Name of each Keaney, Day	presentatives Findividual who acted as a lobbyist in t Name	this issue area	No
House of Reg Senate USTR 18. Name of each Keaney, Dav Warr, David	presentatives • individual who acted as a lobbyist in (Name id Richard	this issue area	<u>No</u>
House of Reg Senate USTR 18. Name of each Keaney, Dav Warr, David Thompson, 1	presentatives • individual who acted as a lobbyist in (Name id Richard	this issue area	No No No
House of Reg Senate USTR 18. Name of each Keaney, Dav Warr, David Thompson, 1	presentatives • individual who acted as a lobbyist in (Name id Richard	this issue area	No No No
House of Reg Senate USTR 18. Name of each Keaney, Dav Warr, David Thompson, 1	presentatives • individual who acted as a lobbyist in (Name id Richard	this issue area	No No No

19. Interest of each foreign entity in the specific issues listed on line 16 above 💦 🕺 Check if None

Signature		Date			,	
Printed Name and Title	Richard Thompson - Vice President, Government Affairs		Page	5	of	22

Self	
ν η	Data
	H.R.1225, United States Patent and Trademark Office Reauthorization Act, Fiscal Year 2000, Monitor the effect of the bill on the pharmaceutical industry. Hatch/Waxman Reform, protecting interests of innovator companies. Protection of Data Exclusivity Agreement, monitoring bills that might impact on Cooperative Research and Development Agreements (CRADA).
	·
	on Issues Issues

Page 6 of 22

-3. I.s.

egistrant Name:	Bristol-Myers Squibb Company	000(23000780	
lient Name:			
OBBYING AC	TIVITY. Select as many codes as necessa	iry to reflect the general issue areas in which the registrant ting period. Using a separate page for each code, provid	
 General issu 	e area code CSP (one per page	a)	
science" in S.1075, Silic	ilicone Breast Implant Research and In breast implant llability cases.	formation Act, Supporting efforts to limit the ability to mation Act, Supporting efforts to limit the ability to at	
	Congress and Federal agencies contacted presentatives	C Check if None	
). Name of eac	It individual who acted as a lobbyist in thi: Name	Covered Official Position (if applicable)	New
Keaney, Da			
Thompson,			No
Ryan, John			No
Cerezza, M			No No
	ichael		
		**	í
	······		······
	······································	· · · · · · · · · · · · · · · · · · ·	
Interact of ea	ch foreign entity in the specific issues liste		
		THE ON THE AND THE AND THE OTHER AND THE OTHER AND THE A	
		Dute	
gnature			
	Title Richard Thompson - Vice Presid	Icot, Government Affairs	June 14 . 4 10

Registrant Name:	Bristol-Myers Squibb Company	
Client Name:		
ingaged in lobbyi	FIVITY. Select as many codes as necessary to ref ag on behalf of the client during the reporting peri uested. Attach additional page(s) as needed.	floct the general issue areas in which the registrant ixed. Using a separate page for each code, provide
6. Specific Lob	e area code <u>ENG</u> (one per page) bying issues lectric Consumers' Power To Choose Act of 19	49. Supporting electricity decomination
		and the send contract of the sense of the
	Congress and Federal agencies contacted presentatives	C Check if None
Senate		
8. Name of each	a individual who acted as a lobbyist in this issue a	rea .
	- Name	Covered Official Position (if applicable)
Skrabut, Lu		
		·······
·····		
		I
9. Interest of ca	th foreign ontity in the specific issues listed on lin	e 16 above 🛛 🗶 Check if None
9. Interest of ca	th foreign ontity in the specific issues listed on lin	ie 16 above 🐹 Check if None
ខ្មែរាមបាជ	ch foreign entity in the specific issues listed on lin Title Richard Thompson - Vice President, Go	Date 8/11/2000

-	Bristol-Myers Squibh Company	000(23000780	
lient Name:	Self	······	
ngaged in lobby		cessary to reflect the general issue areas in which the registrant eporting period. Using a separate page for each cude, provide needed.	
	ue area code ENY (one per		
 Specific La H.R.1390, 		on and Local Authority Act of 1999, Opposing RCRA reform.	
,		and Local Addition by Fact of \$755 (Typology Coxet Februar	
۰			
	f Congress and Federal agencies contac lepresentatives	ated 🖆 Check if None	
) b [6			
 Name of each 	ich ladividual who acted as a lobbyist i	n this issue area	
 Name of each 	ich ladividual who acted as a lobbyist i Name	n this issue area	N
 Name of ea Skrabut, I. 	Nome	Covered Official Pesition (if applicable)	
	Nərne	Covered Official Pesition (if applicable)	Ne Ne
	Nərne	Covered Official Pesition (if applicable)	N
	Name MCY	Covered Official Pesition (if applicable)	N
	Nərne	Covered Official Pesition (if applicable)	N
	Name MCY	Covered Official Position (if applicable)	N
	Name MCY	Covered Official Position (if applicable)	N
Skrabut, I	Name MCY	Covered Official Position (if applicable)	N
Skrabut, I	Name	Covered Official Pesition (if applicable)	N
Skrabut, I	Narne	Covered Official Pesition (if applicable)	N
Skrabut, I	Name	Covered Official Pesition (if applicable)	N
Skrabut, I	Narne	Covered Official Pesition (if applicable)	N
Skrabut, I	Narne	Covered Official Pesition (if applicable)	N
Skrabut, I	Name	Covered Official Position (if applicable)	N
Skrabut, I Skrabut, I D. leseress of c	Narne	s listed on line 16 above M Check if None	

S.2466, To z by certain fo	bying issues rican Growth and Opportunity Act, Advocate p equire the United States Trade Representative weign countries on prescription drugs, Advoca	position for the protection of intellectual property to enter into negotiations to eliminate price contr te for the elimination of foreign price controls, sition for the protection of intellectual property r	ols imposed
Department Food & Dra House of Ro Senate U.S. Agency U.S. Depart	Congress and Federal agencies contacted of Commerce g Administration presentatives for International Development ment of State Representative	Check if None	
 Name of eac 	h individual who acted as a lobbyist in this issue a	PEA Covered Official Position (if applicable)	Nev
Keancy, Da	rid		No
· Wart, David			No
Thompson,	Richard		No
	<u></u>		No
Carozza, Mi			
Carozza, Mi			

1947 24 T

.

.

តា	Description	Data
	Lobhying Essnes	Belgium dioxin contamination. Lobbied to reverse ban on importation of certain products. Southern Africa AIDS Initiative: Assist South Africa, Botswana, Namibia, Lesotho and Swazilano to find solutions for women and children suffereing from the HIV/AIDS epidemic. Biological Weapons Convention Enforcement Issues: Ensure that an equitable and reasonable compliance protocol is adopted. New Zealand Pricing Scheune: Lobbied to reverse pricing actions that would affect the reimborscement of certain pharmacentical products in the country.
		Page 11 of 22

000(23000780

egistrant Name:	000(23)000780 Bristol-Myers Squibb Company	
ient Name;	Self	
gaged in lobbyi	TIVITY. Select as many codes as necessary to reflect the general issue areas in which the registran ng on behalf of the client during the reporting period. Using a separate page for each code, provid prested. Attach additional page(s) as needed.	
5. General issue		
S.2553, Dep 2001, Advoc Coopreratai H.R.4461, A 2001, Advoc H.R.4577, D 2001, Advoc Coopreratai	bying issues mnium Digital Commerce Act, Advocate for adequate protections for industry interests. artiments of Lubor, Health and Human Services, and Education, and Related Agencies Appro- ate increased funding for the NIH and fair treatment for pharmaceutical companies that enter ive Research Agreements and Development Agreements (CRADA's) griculture, Rural Development, Food and Drug Administration, and Related Agencies Appro- ate for fair treatment in WiC program. repartments of Labor, Health and Human Services, and Education, and Related Agencies Appro- ate for fair treatment in WiC program. repartments of Labor, Health and Fair treatment for pharmaceutical companies that enter interessed funding for the NIH and fair treatment for pharmaceutical companies that enter ive Research Agreements and Development Agreements (CRADA's) initiampering Act of 1999, Advocate for the prohibition of unauthorized destruction of produ	er into priations Act, propriations Act, er into
Department Department	Congress and Federal agencies contacted Check if None of Agriculture of Health and Human Services presentatives	
. Name of eac	h individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable)	
	Name Covered Official Position (if applicable)	
Nome of each Thompson,	Name Covered Official Position (if applicable) Richard	No
Thompson,	Name Covered Official Position (if applicable) Richard	
Thompson, Cerozza, Mi	Name Covered Official Position (if applicable) Richard	No No
Thompson, Carozza, Mi	Name Covered Official Position (if applicable) Richard	No No
Thompson, Carozza, Mi	Name Covered Official Position (if applicable) Richard	No No
Thompson, Carozza, Mi	Name Covered Official Position (if applicable) Richard ichael rid	No No
Thompson, I Carozza, Mi Kcaney, Dav	Name Covered Official Position (if applicable) Richard ichael rid	No No
Thompson, I Carozza, Mi Kcaney, Dav	Name Covered Official Position (if applicable)	No No

10 X

۰,

000(23000780

Client I	lient Name: Self	
ltem	Description	Data
16	Lobbying Issues	H.R.4169, Worker Economic Opportunity Act, Advocate for greater worker participation in stock option plans.
16	Lobbying Issues	S.2536, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2001, Advocate for fair treatment in WIC program.
¥6	Lobbying Issues	5.2323, Worker Economic Opportunity Act, Advocate for greater worker participation in stock option plans.
16	Lobbying Issues	H.R.4576, Department of Defense Appropriations Act, 2001, Advocate for the protection and use of information for medical research.
16	Lobbying Issues	H.R.830, Imported Food Safety Act of 1999, Monitor bill and advocate position that protect the company's products and the best interests of the consumer.
16	Lobbying Issues	H.R.1612, Consumer Food Safety Act of 1999, Monitor bill and advocate position that protect the company's products and the best interests of the consumer.
16	Lobbying Issues	S.1123, Imported Food Safety Improvement Act, Monitor bill and advocate position that protect the company's products and the best interests of the consumer.
16	Lobbying Issues	S.1126, Imported Food Safety Improvement Act of 1999, Monitor bill and

		Conconnect
16	Lobbying Issues	S.1126, Imported Food Safety Improvement Act of 1999, Monitor bill and advocate position that protect the company's products and the best inferests of the
		consumer.
16	Lobbying Issues	H.R.1320, Millennium Digital Commerce Act, Advocate for adequate protections for industry interests.
16	Lobbying Issues	H.R.1714, Electronic Signatures in Global and National Commerce Act, Advocate
		for adequate protections for industry interests.
16	Lobbying Issues	H.R.4049, Privacy Commission Act, Advocate for the protection and use of information for medical research.
\$6	Lobbying Issues	H.R.4585, Medical Financial Privacy Protection Act, Advocate for adequate protections and use of information for medical research.
16	Lobbying Issues	H.R.4180, Library of Congress Financial Management Act of 2000, Advocate for greater worker participation in slock option plans.
	1	

Page 13 of 22

· ·		000/23 000780	
Registrant Name	Bristol-Myers Squibb Company		
Client Name:	Self		
engaged in lobby	CTIVITY. Select as many codes as necessary to reflec- ying on behalf of the client during the reporting period. equested. Attach additional page(s) as needed.	t the general issue areas in which the registrant	
15. General iss	ue area code <u>HCR</u> (one per page)		
S. 1462, To order of ce Medicare I H.R. 547, T research. S. 1091, Per S. 118, Con medicat re S. 881, Med the industr	riain covered products for personal use from Cana seneficiaries. 'axpayers' Cancer Research Funding Act of 1999, M diatric Research Initiative Act of 1999, Monitor the sumer Involvement in Breast Cancer Research Act search.		dica) ch.
Health Ca	Congress and Federal agencies contacted re Finance Administration - HCFA representatives	Check if None	

18. Name of each individual who acted as a tobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		Ne
Keaney, David		No
Thompson, Richard		No
Ryan, john	·	No
Skrabut, Lucy		No
	· · · · · · · · · · · · · · · · · · ·	
	· · · · · · · · · · · · · · · · · · ·	
19. Interest of cach foreign entity in the specific issues liste	 ed on line 16 above 🛛 🔀 Check if None	
Signature	Date 8/11/2000	

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 14 of 22

Client Name:

Self

000(23000780

<u>- 60 -</u>	Description	Date
5	Labbying Issues	S.578, Health Care PIN Act, Advocate positions that protect an individual's right
		to privacy and the industry's need to access data essential for medical research.
6	Lobbying Issues	S.573, Medical Information Privacy and Security Act, Advocate positions that protect an individual's right to privacy and the industry's need to access data
		essential for medical research.
5	Lobbying Issues	H.R.1057, Medical Information Privacy and Security Act, Advocate positions that
	- ~	protect an individual's right to privacy and the industry's need to access data
		essential for medical research.
6	Lobbying Issues	H.R.306, Genetic Information Nondiscripting in Health Insurance Act of 1999, Monitor the effect of the bill on medical research.
6	Labbying Issues	HURLOS the effect of the birt of internal research. H.R.293, Genetic Information Health Insurance Nondiscrimination Act of 1999,
		Monitor the effect of the bill on medical research.
	Lobbying Issues	H.R.3240, Drug Import Fairness Act of 1999, Lobbied on Medicare coverage
		regulations.
	Lobbying Issues	H.R.1109, Medicare Outpatient Prescription Drug Coverage Act of 1999, Lobbled on Medicare coverage regulations.
6	Lobbying Issues	on wentere coverage reganitions. H.R.886, Medicare Prescription Drug Coverage Act of 1999, Lobbied on Medicare
	booksynnig taobte	coverage regulations.
6	Lobbying Issues	S.1895, Medicare Preservation and Improvement Act of 1999, Lobbied for
		pharmaceutical benefits for Medicare beneficiaries,
	Lobbying Issues	ILR.2782, Seniors Prescription Insurance Coverage Equity (SPICE) Act of 1999,
6	Lobbying Issues	Lobbied for pharmaccutical benefits for Medicare beneficiaries. H.R.723, Making Affordable Prescriptions Available for Seniors Act, Lobbied for
	Extraction and a second	pharmaceutical benefits for Medicarc beneficiaries.
,	Lobbying Issues	H.R.664, Prescription Drug Fairness for Seniors Act of 1999, Lobbied for
		pharmaccutical benefits for Medicare beneficiaries.
	Lobbying Issues	H.R.626, Health Care Research and Development and Taxpayer Protection Act,
		Monitor and advocate positions that will not adversely affect the pharmacentical industry.
6	Lobbying Issues	assury. H.R.805, Generic Drugs Access Act of 1999, Monitor and advocate positions that
	Press, and restrict	will not adversely affect the pharmaceutical industry.
i	Lobbying Issues	H.R.3426, Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of
		1999, Lobby to improve patient access to cancer therapies in hospital outputient
1	Lobbying Issues	departments. N. P. 2427 Constitution interview in Market Terretory and Terretory and Terretory and Terretory and Terretory a
•	1.000 ying Issues	H.R.2457, Genetic Nondiscrimination in Health Insurance and Employement Act of 1999, Monitor the effect of the bill on medical research.
	Lobbying Issues	H.R.1596, Consumer Involvement to Breast Cancer Research Act, Monitor the
		bill and advocate positions that promote medical research.
•	Lobbying Issues	H.R.1885, International Prescription Drug Parity Act, Lubbied for
6	T abbada a taman	pharmaccutical benefits for Medicare beneficiaries.
	Lobbying Issues	H.R.2925, Medicare Reneficiary Prescription Drug Assistance and Stop-Loss Protection Act of 1999, Lobbled for pharmaceutical benefits for Medicare
		beneficiaries.
	Lobbying Issoes	S.1480, Seniors Prescription Insurance Coverage Equity (SPICE) Act of 1999,
		Lobbled for pharmaceutical benefits for Medicare beneficiaries.
5	Lobbying Issues	H.R.2488, Taxpayer Refund and Relief Act of 1999, Lobbled for pharmaceutical
	Lobbying Issues	benefits for Medicare beneficiaries. H.R.1495, Access to Prescription Medications in Medicare Act of 1999, Labbied
		for phormaccutical benefits for Medicare beneficiaries.
5	Lobbying Issues	H.R.1204, Environmental Equalization and Energy Security Act of 1999, Lobbied
,		for pharmaceutical benefits for Medicare beneficiaries.
	Lobbying Issues	S.841, Access to Rx Medications in Medicare Act of 1999, Lobbied for
	Lobbying Issues	pharmaceutical benefits for Medicare beneficiaries. S.1322, Genetic Nondiscrimination in Health Insurance and Employment Act of
	source in the same of	1999, Monitor the effect of the bill on medical research.
	Lubbying Issues	S.1429, Taxpayer Refund Act of 1999, Lobbied for pharmaceutical benefits far
		Medicare beneficiaries.

ادیے مرد

Client Name:

ı.

Self

-		

000(23000780

Client	Name: Self	
ltem	Description	Data
16	Lobbying Issues	H.R.2030, Medicare Patient Access to Technology Act of 1999, Labbied on Medicare coverage regulations.
16	Lobbying Issues	H.R.785, Biomedical Research Assistance Volumary Option Act, Monitor the bili and advacate positions that promote medical research.
16	Lobbying issues	S.1535, Medicare Ensuring Prescription Drugs for Seniors Act of 1999, Lobbled on Medicare coverage regulations.
16	Lobbying Issues	S.1837, Healthy Seniors Act of 1999, Lobbled on Medicare coverage regulations.
16	Lobbying Issues	H.R.1388, Medicare Cancer Clinical Trial Coverage Act of 1999, Monitor the bill and advocate positions that promote medical research.
16	Lobbying Issues	S.1788, Medicare, Medicaid, and SCHIP Adjustment Act of 1999, Lobby to improve patient access to cancer therapies in hospital outpatient departments.
16	Lobbying fasues	R.R.2927, ABordable Prescription Drugs Act, Lobbled on Medicare coverage regulations.
16	Lobbying issues	H.R.3194, Making consolidated approprintions for the fiscal year ending September 30, 2000, and for other purposes, Lobbled to improve patient access to cancer therapies in isospital outpatient departments.
16	Lobbying Issues	H.R. 3983, Helping to Improve Technology Education and Achievement Act of 2000, Advocate for sufficient visus for medical researchers.
16	Lobbying Issues	H.R.4227, Technology Worker Temporary Relief Act, Advocate for sufficient visus for medical researchers.
16	Lobbying Issues	5.2045, American Competitiveness in the Twenty-first Century Act of 2080, Advocate for sufficient visas for medical researchers.
16	Lobbying Issues	S.2378, Stop All Frequent Errors (SAFE) in Medicare and Medicald Act of 2000, Monitor for impact on the industry.
16	Lobbying Issues	S.2015, Stem Cell Research Act of 2000, Manitor for the impact on medical research.
16	Lobbying Issues	H.R.1796, Medicare Chranic Disease Prescription Drug Benefit Act of 1999, Lobbied on Medicare coverage regulations.
16	Lobbying issues	B.R.3075, Medicare, Medicaid, and SCHIP Salanced Budget Refinement Act of 1999, Lobby to improve patient access to concer therapies in hospital outpatient departments.
16 16	Lobbying Issues	\$.2237, Seniors' Security Act of 2000, Lobbied on Medicare coverage regulations.
10	Lobbying issues	S.543, Genetic Information Nondiscrimination in Health Insurance Act of 1999, Monitor the effect of the bill on medical research.
16	Łobbying izsues	S.1191, International Prescription Drug Parity Act, Lobbied on Medicare coverage regulations,
16	Lobbying Issues	S.696, Medicare Prescription Drug Coverage Act of 1999, Lobbied on Medicare coverage regulations.
16	Łobbying Issues	S.1626, Medicare Patient Access to Technology Act of 1999, Lobbied on Medicare coverage regulations,
16	Lobbying Issues	H.R.4686, Fair Balance Prescription Drug Advertisement Act of 2800, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	5.1795, Drug Gap Insurance Act for Seniors Act of 1999, Labbled on Medicare coverage regulations.
16	Lobbying Issues	5.2753, Medicare Expansion for Needed Drugs (MEND) Act of 2000, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	5.2758, Medicare Outpatient Drug Act of 2000, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	5.2520, Medichae Equity and Drug Safety Act of 2000, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	5.2464, Prescription Drug Fairness Act, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	B.RES.435, Expressing the sense of the House of Representatives that Medicare beneficiaries should have access to outpatient prescription drug coverage, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	B.R.4234, Prescription Drug Assistance Act of 2000, Lobbled on Medicare coverage regulations.
		P
	I .	as Page

۰.

Registrant Name: Bristol-Myers Squibb Company

000(23000780

-

Description	Data .
Lobbying Issues	H.R.3665, Prescription Price Equity Act of 2000, Lobbied on Medicare coverage
Lobbying Issues	regulations. S.2466, To require the United States Trade Representative to enter into negotiations to eliminate price controls imposed by certain foreign countries on
Lobbying Issues	 prescription drugs, Lobbied on Medicare coverage regulations, Medicare Outpatient Payment Regulations, Jobby on regulations governing Medicare Outpatient Payment Regulations, Jobby on regulations governing Medicare Ostomy Regulations, Jobby on coverage and payment for ostomy products. JLR.4776, Medicare Guaranteed and Defined Rx Benefit and Health Care Providor Relief Act of 2000. Lobbied on Medicare coverage regulations. H.R.4743, Drug Availability and Health Care Access Act. Lobbied on Medicare coverage regulations. H.R.4764, To eliminate price controls imposed by foreign countries on Rx drugs. H.R.4772, Pharmaceutical Products Price Equity Act. Lobbied on Medicare coverage regulations. S.2836, Medicare Rx Drug Discount and Security Act. Lobbied on Medicare coverage regulations.
}	
	Page

1.1.2.2

	Bristol-Myers Squibb Company		
lient Name:	<u>Self</u>		
		y to reflect the general issue areas in which the registrant	
	ag on behalf of the chent during the reporti- posted. Attach additional page(s) as needed	ng period. Using a separate page for each code, provide	e
	e area code <u>LAW</u> (one per page)		
suits. H.R.2326, H	Action Fairness Act of 1999, Support the Juman Cloning Research Prohibition Act	e passage of legislation to ensure fair treatment of clas , Monitor the effect of the bill on the legitimate medic onitor the effect of bill on the legitimate medical reser	al research.
	Congress and Federal agencies contacted presentatives	Check if None	
3. Name of eac	h individual who acted as a lobbyist in this		ĺ sta
3. Name of eac	h individual who acted as a lobbyist in this Name	issue area Covered Officest Position (if applicable)	
			New No
	Name Vid	Covered Offices) Position (if applicable)	
Keaney, Da	Narze 	Covered Offices) Position (if applicable)	No
Keaney, Da	Narze 	Covered Offices) Position (if applicable)	No
Keaney, Da	Narze 	Covered Offices) Position (if applicable)	
Keansy, Da	Narze 	Covered Offices) Position (if applicable)	No
Keansy, Da	Narze 	Covered Offices) Position (if applicable)	No
Keansy, Da	Narze 	Covered Offices) Position (if applicable)	No
Keanay, Da Ryan, John	Narze 	Covered Offices Position (if applicable)	No
Keaney, Day Ryan, John . Interest of ca	Name	Covered Officest Position (if applicable)	No

Registrant Name:	Bristol-Myers Squibb Company	000123000780	
Client Name:	Self		
engaged in lobbyin	WITY, Select as many codes as necessa	ary to reflect the general issue areas in which the registrant ting period. Using a separate page for each code, provide	
15. General issue	area code MMM (one per page	e) ·	
patient and t S.1344, Patie industry's ba H.R.2900, Cl best interests S.1788, Medi hospital outp H.R.1544, Te Medicare ba	he industry's hest interests. n4s' Bill of Rights Pius Act (Public Pri- st interests. can Smokestacks Act of 1999, Monitor , care, Medicaid, and SCHIP Adjustme atient departments. require the Secretary of Health and F	cal Year 2001, Monitor bill and advocate positions that pr nt), Monitor bill and advocate positions that protect the pa r bill and advocate positions that protect the patient and th nt Act of 1999, Lobby to improve patient access to cancer Human Services to establish a demonstration project to pr apect to various courses of treatment, Monitor bill and an s best interests.	ationt and th ne industry's therapies in ovide
	ongross and Federal agencies contacted Finance Administration - HCFA presentatives	Check if None	
8. Name of eact	individual who acted as a lobbyist in thi	is issue area	·
8. Name of eact	individual who acted as a lobbyist in thi Name	is issue area Covered Official Position (if upplicable)	New
 Name of each Thompson, J 	Name	:	New No
Thompson, J	Name	Covered Official Position (if applicable)	
Thompson, J	Name Lichard	Covered Official Position (if applicable)	No
Thompson, J Carozza, Mie	Name Lichard	Covered Official Position (if applicable)	Na
Thompson, J Carozza, Mi Keancy, Dav	Name Lichard	Covered Official Position (if applicable)	No No No

Signature	······	Date 8/11/2000
Printed Name and Title	Richard Thompson - Vice President, Government Affairs	Page 19 of 22

1 1 12 1

.

000(23000780

Т

tem	Description	Data
6	Lobbying Issues	H.R.448, Patient Protection Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
6	Lobbying fissues	H.R.358, Patients' Bill of Rights Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests,
6	Lobbying Issues	S.751, Seniors Safety Act of 1999, Manitor bill and advocate positions that protect the patient and the industry's best interests.
6	Lobbying Issues	S.374. Promoting Responsible Managed Care Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
6	Lobbying Issues	S.326, Patients' Bill of Rights Act, Monitor bill and advocate positions that protect the patient and the industry's best interests.
6 .	Lobbying Issues	S.309, Patients' Bill of Rights Plus Act, Monitor bill and advocate positions that protect the patient and the industry's best interests.
6	Lobbying Issues	5.240, Patients' Bill of Rights Act of 1999, Monitor bill and advacate positions that protect the patient and the industry's best interests.
6	Lobbying Issues	S.6, Patients' Bill of Rights Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
6	Lobbying Issues	Medicure Outpatient Payment Regulations, lobbying on regulations governing Medicare reimbursement of hospital outpatient prescription drugs. Medicare Ostomy Regulations, lobby on coverage and payment for astomy products.

Page 20 of 22

egistraat Name:	Bristol-Myers Squibb Company		
lient Name:	Self		
igaged in lobbyir		reessary to reflect the general issue areas in which the registrant reporting period. Using a separate page for each code, provide needed.	
 General issue Specific Lobi R&D Tax Ci China/Puert products. 	bying issues redit, to make permanent the resea		actuerd
	Congress and Federal agencies conta presentatives	eted Ü Check if None	
3. Name of each	n individual who acted as a lobbyist	in this issue area	
	Name	Covered Official Position (if applicable)	New
Warr, David	L		No
Thompson, I	Richard		No
Carozza, MS	chael		No
Keaney, Dav	/iđ		No
Ryan, John			No
i. Interest of car	ch foreign entity in the specific issue	is listed on line 16 above 🛛 🔀 Check if None	
gnature		Date 8/11/2000	
interl Morea and	Title Richard Thompson - Vice I	President, Government Affairs Pag	e 21 of 2

1 T 14

tegistrant Nat	me: Bristol-Myers Squibb Compa	000(23 000780	
lient Name:	Self		
OBBYING .	ACTIVITY. Select as many codes as	is necessary to reflect the general issue areas in which the registrant	
	obying on behalf of the client during t requested. Attach additional page(s)	the reporting period. Using a separate page for each code, provide) as needed.	
	issue area code TRD (one	e per page}	
S.666, A3 economia H.R.434, economia Canada Canada China/Po products Data Exe	es of sub-Sabaran Africa. , African Growth and Opportunity es of sub-Saharan Africa. Palent Issue: Canada's failure to p uerto Rico Tariff Issue: China hus I 5. clusivity: South Africa, The Nether.	ct, Establishes a U.S. policy of trade and investment with the emerging v Act, Establishes a U.S. policy of trade and investment with the emergi provide 20 year potent term in accordance with GATT/TRIPS. levied much higher Chinese customs duties on Paerto Rico manufactu riands, Canada, lobby Congress, Department of State and U.S. Trade provisions under GATT TRIPS provision.	ng
House of Schale	of Congress and Federal agencies co (Representatives		
	ariment of Health and Human Ser d and Drug Administration		
The Foo		. ·	New
The Foo 8. Name of	d and Drug Administration each individual who acted as a lobby	yist in this issue area	New No
The Foo 8. Name of	d and Drug Administration each individual who acted as a lobby Name - on, Richard	yist in this issue area	
The Foo 8. Name of	d and Drug Administration each individual who acted as a lobby Name - on, Richard David	yist in this issue area	No
The Foo 8. Name of	d and Drug Administration each individual who acted as a lobby Name - on, Richard David	yist in this issue area	No No
The Foo 8. Name of	d and Drug Administration each individual who acted as a lobby Name - on, Richard David	yist in this issue area	No
The Foo 8. Name of	d and Drug Administration each individual who acted as a lobby Name - on, Richard David	yist in this issue area	No No
The Foo 8. Name of	d and Drug Administration each individual who acted as a lobby Name - on, Richard David	yist in this issue area	No No
The Foo 8. Name of	d and Drug Administration each individual who acted as a lobby Name - on, Richard David	yist in this issue area Covered Official Position (if applicable)	No No
The Foo 8. Name of Thompse Keaney, Warr, D 9. Interest of	d and Drug Administration each individual who acted as a lobby Name ' on, Richard David vavid	yist in this issue area Covered Official Position (if applicable)	No No